Microplate Dx Limited
United Kingdom
- Glasgow, Lanarkshire
- 12/09/2023
- Seed
- $3,117,000
Microplate Dx Limited specialises in rapid antibiotic susceptibility testing diagnostics, enabling clinicians, at the point-of-care, to confidently select the best choice of antibiotic to treat a patient’s infection in a matter of minutes, significantly quicker than the current gold standard technology which takes at least 2 days. Our award-wining, platform diagnostic test helps reduce the major global health threat of antimicrobial resistance and ultimately, saves lives.
- Industry Medical Equipment Manufacturing
- Website https://microplatedx.com/
- LinkedIn https://www.linkedin.com/company/microplate-dx-limited/about/
Related People
Stuart HannahFounder
United Kingdom -
Greater Glasgow Area
CEO - Microplate Dx Limited.
Developing a rapid, cost-effective, direct-from-sample, antibiotic susceptibility test, which quickly identifies the best choice of antibiotic for a particular infection in minutes, significantly quicker than the current gold standard of days.
Juvena Therapeutics | $33,500,000 | (Jan 14, 2026)
bricks.sh | $1,863,303 | (Jan 14, 2026)
Allos | $5,000,000 | (Jan 14, 2026)
PayMedix | $33,000,000 | (Jan 14, 2026)
WeatherPromise | $12,800,000 | (Jan 14, 2026)
Diffraqtion | $4,200,000 | (Jan 14, 2026)
WithCoverage | $42,000,000 | (Jan 14, 2026)
Nodu | $1,450,000 | (Jan 14, 2026)
Cloudforce | $10,000,000 | (Jan 14, 2026)
Converge Bio | $25,000,000 | (Jan 14, 2026)
JetZero | $175,000,000 | (Jan 14, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)